DV10BB1
Brachytherapy Prostate to Unidirectional Source with Palladium 103 (Pd-103), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | V Male Reproductive System |
| Operation | 1 Brachytherapy |
| Body Part | 0 Prostate |
| Approach | B Low Dose Rate (LDR) |
| Device | B Palladium 103 (Pd-103) |
| Qualifier | 1 Unidirectional Source |
Procedure Overview
Brachytherapy of the male reproductive system involves placing radioactive sources, most often tiny seeds, directly into or immediately next to the prostate gland so the radiation dose is concentrated at very close range while tissue farther away receives comparatively little exposure. Low-dose-rate implants are typically permanent, with the seeds left in place indefinitely as their radioactivity decays over weeks to months, while high-dose-rate brachytherapy uses temporary catheters that deliver a strong dose over a short session and are then removed. It is used primarily for localized prostate cancer, either alone for lower-risk disease or combined with external beam radiation for higher-risk cases.
The procedure is performed under image guidance, usually transrectal ultrasound, with the patient under anesthesia while the physician positions needles or catheters to place the sources precisely.
Anatomy & Axis Detail
Prostate
Brachytherapy of the prostate involves placing radioactive sources directly into the gland, either as permanent low-dose-rate seeds or temporary high-dose-rate catheters, taking advantage of the prostate's fixed, accessible position between the bladder and rectum for transperineal implantation under image guidance. This technique allows a highly concentrated dose to be delivered to the gland itself while limiting exposure to the adjacent rectal wall and urethra compared to purely external approaches, making it a common option for localized, lower-risk prostate cancer either alone or combined with external beam therapy. Because seed or catheter placement requires precise mapping of prostate volume and urethral course, transrectal ultrasound or MRI guidance is typically used during the procedure. Patients receiving permanent seed implants require specific radiation safety counseling given the retained source material, a consideration unique to this delivery method at this body part.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Palladium 103 (Pd-103)
Palladium-103 is another low-dose-rate isotope used in permanent interstitial seed implants, chiefly for prostate brachytherapy, but its shorter half-life (about 17 days) delivers its therapeutic dose faster than I-125. Clinicians may favor it for higher-grade or faster-growing tumors where a more concentrated early dose is desired, while I-125 remains preferred for lower-risk, slower disease.
Qualifier: Unidirectional Source
This qualifier specifies that a unidirectional radioactive source is used in radiation therapy, meaning the source emits radiation in one direction rather than uniformly, as with certain brachytherapy applicators. It distinguishes this directional delivery technique from standard radiation sources, which do not require this added qualifying detail.
Coding & Documentation
The coder must confirm from the procedure note whether the source is temporary (high-dose-rate afterloading) or permanent (low-dose-rate seed implant), since documentation of "seed implant" versus "HDR brachytherapy" affects the qualifier even though the root operation is the same. Physician documentation of the isotope used (such as iodine-125 or palladium-103 for permanent seeds) helps confirm the approach was brachytherapy rather than another modality. A common error is coding the diagnostic ultrasound guidance or the separate anesthesia encounter as part of the radiation procedure itself rather than coding only the source placement.